<p>中國蘇軒堂藥業（NASDAQ:SXTC - 獲取免費報告）在週三的午盤交易中股價創下 52 周新低。該股最低交易價為 3.96 美元，最後交易價為 3.8530 美元，成交量為 155008 股。該股此前收盤價為 4.53 美元。</p>
<h2>華爾街分析師觀點</h2>
<p>另外，Weiss Ratings 在 10 月 8 日的報告中重申了對中國蘇軒堂藥業股票的 “賣出（e+）” 評級。根據 MarketBeat 的數據，一位股票研究分析師對該股給予了賣出評級，該股的平均評級為 “賣出”。</p>
<p><strong>獲取我們關於 SXTC 的最新報告</strong></p>
<h2>中國蘇軒堂藥業股票表現</h2>
<p>該公司的 50 日移動平均價格為 149.19 美元，200 日移動平均價格為 202.13 美元。</p>
<p>中國蘇軒堂藥業（NASDAQ:SXTC - 獲取免費報告）最近一次發佈財報是在 12 月 31 日。該公司報告季度每股收益（EPS）為（4.50）美元。該季度的營業收入為 31 萬美元。</p>
<h2>機構資金流入和流出</h2>
<p>一家機構投資者最近增加了在中國蘇軒堂藥業股票中的持倉。根據其最近向 SEC 的披露，Virtu Financial LLC 在第三季度將其在中國蘇軒堂藥業（NASDAQ:SXTC - 免費報告）的持股增加了 107.5%。該機構投資者在此期間購買了 15013 股後，持有該公司 28983 股股票。根據其最近的 SEC 文件，Virtu Financial LLC 在中國蘇軒堂藥業的持股價值為 46000 美元。目前，5.02% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>中國蘇軒堂藥業公司簡介</h2>
<p>（獲取免費報告）</p>
<p>中國蘇軒堂藥業（NASDAQ:SXTC）是一家總部位於中國的生物製藥公司，專注於基於肽的治療藥物的研究、開發、生產和商業化。該公司的產品線集中於針對腫瘤、內分泌和代謝疾病的新型治療方案。通過利用專有的肽合成和製劑技術，中國蘇軒堂旨在推進下一代生物製劑，以滿足國內外市場未滿足的醫療需求。</p>
<p>該公司的核心產品候選包括長效肽激素和肽藥物偶聯物，旨在提高患者的依從性和治療效果。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，而不是中國蘇軒堂藥業</li>
<li>華爾街對 USAU 持樂觀態度，黃金創下新紀錄！</li>
<li>雷·達里奧建議購買黃金。我説每月從中獲利</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 你的銀行賬户</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>新法律：國會批准數字美元的設立？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在中國蘇軒堂藥業嗎？</h2>
<p>在考慮投資中國蘇軒堂藥業之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄推薦給客户的股票，以便在更廣泛的市場注意到之前購買……而中國蘇軒堂藥業並不在名單上。</p>
<p>雖然中國蘇軒堂藥業目前在分析師中被評為賣出，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

中國蘇軒堂藥業

美國制藥 ETF - iShares

<p>中國蘇軒堂藥業（NASDAQ:SXTC）在交易中達到 52 周新低，報$3.96，收盤價為$3.8530。Weiss Ratings 維持 “賣出（e+）” 評級，分析師的平均評級為 “賣出”。該公司報告上個季度每股虧損$4.50，收入為$0.31 百萬。機構投資者 Virtu Financial 增持 107.5%，持有 28,983 股，價值$46,000。中國蘇軒堂專注於用於腫瘤和代謝疾病的肽類治療，但目前並不被頂級分析師推薦投資</p>

<p>China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $3.96 and last traded at $3.8530, with a volume of 155008 shares traded. The stock had previously closed at $4.53.</p>
<div class="lb-trans"><p>中國蘇軒堂藥業（NASDAQ:SXTC - 獲取免費報告）在週三的午盤交易中股價創下 52 周新低。該股最低交易價為 3.96 美元，最後交易價為 3.8530 美元，成交量為 155008 股。該股此前收盤價為 4.53 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of China SXT Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的報告中重申了對中國蘇軒堂藥業股票的 “賣出（e+）” 評級。根據 MarketBeat 的數據，一位股票研究分析師對該股給予了賣出評級，該股的平均評級為 “賣出”。</p>
</div><p><strong>Get Our Latest Report on SXTC</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 SXTC 的最新報告</strong></p>
</div><h2>China SXT Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>中國蘇軒堂藥業股票表現</h2>
</div><p>The firm has a 50 day moving average price of $149.19 and a two-hundred day moving average price of $202.13.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均價格為 149.19 美元，200 日移動平均價格為 202.13 美元。</p>
</div><p>China SXT Pharmaceuticals (NASDAQ:SXTC - Get Free Report) last posted its earnings results on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million during the quarter.</p>
<div class="lb-trans"><p>中國蘇軒堂藥業（NASDAQ:SXTC - 獲取免費報告）最近一次發佈財報是在 12 月 31 日。該公司報告季度每股收益（EPS）為（4.50）美元。該季度的營業收入為 31 萬美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>An institutional investor recently raised its position in China SXT Pharmaceuticals stock. Virtu Financial LLC increased its holdings in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Free Report) by 107.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 28,983 shares of the company's stock after buying an additional 15,013 shares during the period. Virtu Financial LLC's holdings in China SXT Pharmaceuticals were worth $46,000 as of its most recent SEC filing. 5.02% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一家機構投資者最近增加了在中國蘇軒堂藥業股票中的持倉。根據其最近向 SEC 的披露，Virtu Financial LLC 在第三季度將其在中國蘇軒堂藥業（NASDAQ:SXTC - 免費報告）的持股增加了 107.5%。該機構投資者在此期間購買了 15013 股後，持有該公司 28983 股股票。根據其最近的 SEC 文件，Virtu Financial LLC 在中國蘇軒堂藥業的持股價值為 46000 美元。目前，5.02% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>China SXT Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>中國蘇軒堂藥業公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>China SXT Pharmaceuticals Inc NASDAQ: SXTC is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.</p>
<div class="lb-trans"><p>中國蘇軒堂藥業（NASDAQ:SXTC）是一家總部位於中國的生物製藥公司，專注於基於肽的治療藥物的研究、開發、生產和商業化。該公司的產品線集中於針對腫瘤、內分泌和代謝疾病的新型治療方案。通過利用專有的肽合成和製劑技術，中國蘇軒堂旨在推進下一代生物製劑，以滿足國內外市場未滿足的醫療需求。</p>
</div><p>The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.</p>
<div class="lb-trans"><p>該公司的核心產品候選包括長效肽激素和肽藥物偶聯物，旨在提高患者的依從性和治療效果。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than China SXT Pharmaceuticals</li>
<li>Wall Street Turns Bullish on USAU as Gold Hits New Record!</li>
<li>Ray Dalio Says Buy Gold. I Say Get Paid Every Month From It</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是中國蘇軒堂藥業</li>
<li>華爾街對 USAU 持樂觀態度，黃金創下新紀錄！</li>
<li>雷·達里奧建議購買黃金。我説每月從中獲利</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 你的銀行賬户</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>新法律：國會批准數字美元的設立？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in China SXT Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在中國蘇軒堂藥業嗎？</h2>
</div><p>Before you consider China SXT Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資中國蘇軒堂藥業之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and China SXT Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄推薦給客户的股票，以便在更廣泛的市場注意到之前購買……而中國蘇軒堂藥業並不在名單上。</p>
</div><p>While China SXT Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然中國蘇軒堂藥業目前在分析師中被評為賣出，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

中國蘇軒堂藥業（NASDAQ:SXTC）股價創下 1 年來新低 - 以下是發生的情況